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Abstract
Objective: To evaluate the incidence of pulmonary metastases on chest computed
tomography (CT) in patients with locally advanced pancreatic cancer (LAPC).
Methods: All patients diagnosed with LAPC in a single tertiary center (Erasmus MC)
between October 2011 and December 2017 were reviewed. The staging chest CT scan
and follow‐up chest CT scans were evaluated. Pulmonary nodules were divided into
three categories: apparent benign, too small to characterize, and apparent malignant.
Results: In 124 consecutive patients diagnosed with LAPC, 119 (96%) patients un-
derwent a staging chest CT scan at the initial presentation. In 88 (74%) patients no
pulmonary nodules were found; in 16 (13%) patients an apparent benign pulmonary
nodule was found, and in 15 (13%) patients a pulmonary nodule too small to char-
acterize was found. Follow‐up chest CT scan(s) were performed in 111 (93%) pa-
tients. In one patient with either no pulmonary nodule or an apparent benign
pulmonary nodule at initial staging, an apparent malignant pulmonary nodule was
found on a follow‐up chest CT scan. However, a biopsy of the nodule was incon-
clusive. Of 15 patients in whom a pulmonary nodule too small to characterize was
found at staging, 12 (80%) patients underwent a follow‐up CT scan; in 4 (33%) of
these patients, an apparent malignant pulmonary nodule was found.
Conclusion: In patients with LAPC in whom at diagnosis a chest CT scan revealed either
no pulmonary nodules or apparent benign pulmonary nodules, routine follow‐up chest CT
scans is not recommended. Patients with pulmonary nodules too small to characterize are
at risk to develop apparent malignant pulmonary nodules during follow‐up.
1 | INTRODUCTION
Projections indicate that pancreatic cancer will be the second leading
cause of cancer‐related death by 2030.1 At the time of diagnosis,
15% of patients with pancreatic cancer have (borderline) resectable
disease (stage I or II), whereas 35% of patients present with locally
advanced pancreatic cancer (LAPC; stage III), and 50% of patients
initially present with metastatic disease (stage IV).2 The definition of
LAPC is determined by the extent of tumor contact with the
superior mesenteric artery, celiac artery, superior mesenteric vein,
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and portal vein.3 Moreover, imaging should demonstrate no evidence
of metastatic disease.
A chest computed tomography (CT) scan is more sensitive and
specific in detecting pulmonary metastases than a conventional chest
X‐ray.4 In patients with pancreatic cancer, the National Compre-
hensive Center Network (NCCN) guidelines recommend routine
chest CT scans.5 Chest CT scan in (borderline) resectable pancreatic
cancer, nonetheless, was found to be of no influence on survival.6‐8
Chest CT scans frequently reveal subcentimeter pulmonary nodules
that are often said to be too small to characterize. They impose a
clinical dilemma, as these nodules of uncertain nature induce un-
certainty with regard to their nature and as such carry a huge
emotional burden to patients. These findings often lead to additional
invasive diagnostic tests, which delays the start of treatment and can
impose additional risks to the patients. For example, diagnostic
transthoracic lung biopsies harbor a considerable risk of pneu-
mothorax or intrathoracic bleeding and frequently are found to be
nondiagnostic.9
Moreover, the clinical value of a chest CT scan in LAPC could be
questioned, because systemic chemotherapy is the first‐line treat-
ment for both LAPC and metastatic disease.10 Detection of meta-
static disease in LAPC patients is particularly relevant in the era of
several locoregional treatments for pancreatic cancer, including
radiofrequency ablation, irreversible electroporation, and stereo-
tactic body radiotherapy (SBRT).11 While the benefit of these treat-
ments has not been shown definitively, even their strongest
proponents agree that they are unlikely to benefit patients with
metastatic disease. The aim of this study is to evaluate the yield of
routine chest CT scans in patients with LAPC at initial staging and
during follow‐up.
2 | METHODS
We retrospectively reviewed all consecutive patients diagnosed with
LAPC between October 2011 to December 2017 seen at Erasmus
MC, The Netherlands. The database used for this study was approved
by the Institutional Review Board, and informed consent was waived.
A diagnostic CT scan of the chest and abdomen was performed at
diagnosis and during follow‐up. The CT scan was done on a 128 slice
CT scanner with three phases (unenhanced, late arterial [35 seconds],
and portal venous [70 seconds]) of the upper abdomen after in-
travenous injection of contrast medium. In addition, the lower ab-
domen and chest were scanned in the last phase. The majority of the
staging CT scans were performed in our institute; however,
some patients already underwent a staging CT scan in the hospital of
referral. If the quality of these CT scans was up to the standard and
scan were performed less than 4 weeks before therapy, these scans
were added in our imaging archive and formally reassessed. Other-
wise, the patient underwent a new CT scan in our institute following
the guidelines as described above. Diagnosis of LAPC was according
to the Dutch guidelines.12
All patients with LAPC were offered a treatment consisting of
eight cycles of FOLFIRINOX followed by either conventional or
stereotactic body radiotherapy when no disease progression was
observed on follow‐up scanning. If FOLFIRINOX was not feasible,
other chemotherapy regimens or best supportive care were dis-
cussed with the patient. Usually, follow‐up CT scans were performed
after four and eight cycles of FOLFIRINOX, and 3 months after
radiotherapy. In the case of SBRT, an additional CT scan was per-
formed after 6 months. After this, patients underwent CT scans only
on the indication. Surgery was offered to patients if induction
F IGURE 1 Staging (left) and follow‐up (right) computed tomography scans of patients with nodule too small to characterize (up), and benign
nodule (under) [Color figure can be viewed at wileyonlinelibrary.com]
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therapy downstaged the disease to (borderline) resectable pancreatic
cancer. The Dutch Pancreatic Cancer Group definitions for resect-
ability were used.12
Pulmonary nodules observed during initial and follow‐up CT
scans were divided into three categories: apparent benign, too small
to characterize, and apparent malignant, whereby an apparent benign
nodule was defined as a lesion with homogenous calcification.
A nodule was considered too small to characterize was a noncalcified
nodule under 1 cm, or pleural effusion (Figure 1).8
Comparisons of patient's characteristics between patients with-
out pulmonary nodule or benign nodules versus patients with no-
dules too small to characterize were analyzed using Fisher exact test
for categorical variables, and a nonparametric median test for con-
tinuous variables. Overall survival (OS) was calculated from the date
of first staging CT scan until the death of any cause. The survival
outcome is presented using Kaplan‐Maier and compared logrank in
SPSS (version 21). A P value less than .05 was considered statistically
significant.
3 | RESULTS
In total 124 consecutive patients diagnosed with LAPC between
December 2011 and December 2017 were identified. In 119 (96%)
patients (45% male, median age 64 years [interquartile range—IQR,
56‐70]) a staging chest CT scan was available. The World Health
Organization's performance score was 0 or 1 in 85 (71%) patients.
The tumor was located in the pancreatic head in 73 (61%) of the
patients, in the body in 40 (34%) patients, and in 6 (5%) in the tail.
LAPC diagnosis was based on arterial contact in 74 (62%) patients,
venous contact in 18 (15%) patients, and both venous and arterial
contact in 27 (23%) patients. The median baseline serum level of
CA19‐9 was 233 [IQR, 61‐974] and of CEA 6.3 [IQR, 3.0‐18.3]. All
baseline characteristics are shown in Table 1.
Best supportive care was initiated in 35 (29%) after the initial
diagnosis of LAPC. The reason for initiating the best supportive care
was patients' condition in 20 (57%), and patients' requests in
15 (43%) patients. FOLFIRINOX was given as first‐line treatment in
81 (68%) patients, nab‐paclitaxel and gemcitabine in 2 (2%) patients,
and gemcitabine alone in 1 (1%) patient. Subsequent radiotherapy
was given in 56 (68%) patients after induction chemotherapy. The
reason for not receiving radiotherapy after chemotherapy was pro-
gression after chemotherapy in 13 (50%) patients, and toxicity in
13 (50%) patients. Conventional radiotherapy was given to 19 (34%)
patients, while stereotactic body radiotherapy was given to 37 (66%)
patients. Eventually, seven (6%) patients underwent resection.
In 31 (26%) patients a pulmonary nodule was found on the initial
staging CT scan. In 15 (13%) patients the nodules were classified as
too small to characterize, whereas in 16 (13%) patients the nodules
were classified as apparent benign. The baseline characteristics
gender, age, tumor diameter, tumor location, smoking history, and
baseline serum CA19‐9 and CEA were not associated with the pre-
sence of nodules too small to characterize on staging chest CT scan
(Table 2). A follow‐up chest CT scan was performed in 111 (93%)
patients (Figure 2), the median time between staging and follow‐up
CT scan was 7 months [IQR, 2‐15]. The median number of follow‐up
chest CT scans was 2 [IQR, 1‐4]. In one (1%) patient in whom the
initial CT scan no pulmonary nodule was seen, malignant appearing
pulmonary nodules were seen during follow‐up. The follow‐up chest
CT scan was performed for restaging purposes before the start of
treatment 1 month after a first chest CT scan. However, a biopsy of
one of the nodules was inconclusive. Of the 15 patients in whom the
initial CT scan revealed a pulmonary nodule too small to characterize
on staging imaging, 12 (80%) patients underwent a follow‐up chest
CT scan after a median time of 4 months [IQR, 2‐20]. In four (33%) of
these patients, an apparent malignant pulmonary nodule was ob-
served, which coincided in one patient with the development of liver
metastasis. Whereas, in five (42%) patients no apparent malignant
nodule on follow‐up chest CT scan was found, while three (25%)
patients had unchanged nodules. In these patients, no biopsies or
resections were performed to obtain a pathological confirmation in
any of the radiologically apparent malignant pulmonary nodules. The
indication for these follow‐up scans was restaging in nine (75%) pa-
tients and deterioration of condition in three (25%) patients.
TABLE 1 Baseline characteristics
Baseline characteristics N = 119 (% or IQR)
Age, median 64 [56‐70]
Sex
Male 53 (45)
Female 66 (55)
WHO PS
0‐1 85 (71)
2‐4 34 (29)
Smoking
Yes 33 (28)
Never 38 (32)
Former 42 (35)
Missing 6 (5)
BMI, median 24 [21‐27]
Tumor origin
Head 73 (61)
Body 40 (34)
Tail 6 (5)
Maximum tumor size, mm 37 [30‐44]
LAPC based on
Only arterial 74 (62)
Only venous 18 (15)
Both arterial and venous 27 (23)
Median CA19‐9, µg/L 233 [61‐966]
Median CEA, kU/L 6.3 [3.0‐18.3]
Abbreviations: BMI, body mass index; IQR, interquartile range; LAPC,
locally advanced pancreatic cancer; PS, performance status; WHO, World
Health Organization.
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The CT scan of the three patients with deterioration of condition
showed local progression in one (33%) patients, liver metastases in
one (33%) patients, and liver and peritoneal metastases in one (33%)
patient. Clinical characteristics of the patients with nodules too small
to characterize on first staging chest CT scan are shown in Table 3.
Median follow‐up time for all 119 patients was 36 months (95%
confidence interval [CI], 31‐40), while median OS after first chest CT
scan was 12 months (95% CI, 10‐14). There was no difference be-
tween patients with benign or without pulmonary nodules vs patients
with nodules too small to characterize for receiving chemotherapy
(72% vs 60%; P = .49) or radiotherapy (49% vs 40%; P = .59). The
median OS for patients with pulmonary nodule too small to char-
acterize was 11 months (95% CI, 4‐18) vs 13 months (95% CI, 10‐15)
in patients without these nodules (P = .88) (Figure 3).
4 | DISCUSSION
Staging and restaging chest CT scans are routinely performed in
patients with LAPC. To our knowledge, this is the first study to,
TABLE 2 Comparing clinical characteristics for patients with and without nodules too small to characterize on staging CT scan
Patients with nodules
too small to
characterize (N = 15)
Patients with benign or
without pulmonary
nodules (N = 104) P value
Age, median [IQR] 68.5 [60.7‐70.1] 63.5 [55.6‐69.8] .09
Male gender 54% 43% .58
Smoking (current) 23% 30% .75
Tumor origin (head) 40% 39% 1.00
Maximum tumor size [IQR], mm 37 [35‐47] 37 [30‐44] .81
Median CA19‐9 [IQR], µg/L 244 [169‐1392] 231 [56‐966] .97
Median CEA [IQR], kU/L 5.7 [3.0‐50.5] 6.5 [3.1‐18.0] .96
Chemotherapy 60% 73% .36
Radiotherapy 40% 49% .59
Survival (95% CI), mo 13 (10‐15) 11 (3‐18) .88
Abbreviations: CI, confidence interval; CT, computed tomography; IQR, interquartile range.
F IGURE 2 Flowchart of the study
population. CT, computed tomography; LAPC,
locally advanced pancreatic cancer [Color
figure can be viewed at
wileyonlinelibrary.com]
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retrospectively though, assess and valuate the clinical value of these
CT scans, dividing any observed pulmonary nodule into any of
three categories: apparent benign, too small to characterize, and ap-
parent malignant pulmonary nodules too small to characterize were
seen on first staging chest CT scan in fifteen (13%) patients with LAPC.
In this group of patients, follow‐up chest CT scan revealed a sub-
sequent apparent malignant nodule in four patients. Of these four
patients, one patient had simultaneous a liver metastasis. Thereby,
staging and follow‐up chest CT scan performed in 111 patients gave
additional information only in 3 (3%) patients. All the malignant no-
dules found on follow‐up CT scans were first seen on the staging CT
scan as nodules too small to characterize. These findings suggest that
follow‐up CT scans are only of clinical value if there is a pulmonary
nodule too small to characterize on the first staging CT scan.
In the group with no pulmonary nodules on first staging CT scan,
one (1%) patient showed a possible malignant appearing nodule.
However, there was radiological uncertainty about this diagnosis.
Therefore, the patient underwent a transthoracic biopsy which yiel-
ded no confirmation of a malignancy. The patient started with sys-
temic chemotherapy, but stopped after two cycles due to
deterioration of condition. No other follow‐up chest CT scan were
performed after the restaging CT scan. The patient died eventually
5 months after first chest CT scan, and 2 months after last cycle of
FOLFIRINOX. This case gives more insight about the clinical di-
lemmas of follow‐up chest CT scans in LAPC patients.
The NCCN guidelines advise a staging chest CT scan in all pan-
creatic cancer patients.13 In addition to these guidelines, or maybe to
challenge the evidence of them, retrospective observational studies
have assessed the added value of chest CT scans in patients with
resectable pancreatic cancer.7,8,14 Poruk et al14 showed that in
183 patients with resectable pancreatic cancer and nodules too small
to characterize on the staging CT scan, 16% of the patients subse-
quently developed apparent malignant pulmonary nodules during
routine follow‐up chest CT scans. Nonetheless, there was no differ-
ence in median OS between patients with and without these nodules
too small to characterize. More recently, Mehtsun et al7 showed that
in 451 patients with resectable pancreatic cancer with pulmonary
nodules too small to characterize, subsequent apparent malignant
nodules in was found in only 19 (4%) patients. In this study, there was
also no difference in median OS between patients with and without
pulmonary nodules too small to characterize. In the LAPC setting,
exclusion of metastatic disease is of the essence. Therefore, staging
chest CT scan seems reasonable, especially in the era of local
therapies emerging as possible new treatment for LAPC.15 For
treatment monitoring purposes restaging chest CT scans are
recommended.13 Nonetheless, our study shows that patients without
any pulmonary nodule on staging CT scan only one patient developed
malignant appearing nodules evidence during follow‐up chest CT
scans, without any histopathological proof. Furthermore, only 4% of
the patients showed metastatic pulmonary nodules in follow‐up CT
scans. These restaging chest scans could be an extra burden for pa-
tients, as small nodules could be seen. This could impose additional
stress to these patients, as it could also implicate the clinical man-
agement. Physicians face the decision to do diagnostics on these
nodules or ignore them, keeping in mind that local therapy could be a
futile treatment strategy for these patients. In the current study,
there was no difference in initial treatment management between
patients with and without pulmonary nodules.
The main limitation of our study is its retrospective design, which
implicates that patients who were deemed as metastasized pan-
creatic cancer due to pulmonary metastasis are missed in this study.
Moreover, the definitions used for resectability before and after in-
duction therapy are more conservative than used by NCCN guide-
lines, which could influence the generality of our findings.
Furthermore, the data is obtained from only one institute. None-
theless, our institute is the biggest academic hospital in the Neth-
erlands where most of the patients are referred from nonacademic
hospitals. However, more studies are needed to confirm our findings.
In conclusion, follow‐up chest CT scans added information on
pulmonary metastasis only in 4% of the patients. However, these
nodules were first seen as too small to characterize on staging chest
CT scans. The management and survival of patients with nodules too
small to characterize on staging CT scan did not significantly differ
from patients without these nodules. Routinely follow‐up chest CT
should be questioned, unless undefined pulmonary nodules are found
on staging chest CT scan.
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